These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 6678971)

  • 21. Induction of DNA strand breaks and cross-links by 2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone in Chinese hamster ovary cells.
    King CL; Hittelman WN; Loo TL
    Cancer Res; 1984 Dec; 44(12 Pt 1):5634-7. PubMed ID: 6498824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of 2,5-diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone (BZG, NSC 224070) during a phase I clinical trial.
    Betteridge RF; Bosanquet AG; Gilby ED
    Eur J Cancer; 1990 Feb; 26(2):107-12. PubMed ID: 2138904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells.
    Siegel D; Gibson NW; Preusch PC; Ross D
    Cancer Res; 1990 Nov; 50(22):7293-300. PubMed ID: 2121335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
    Greenberg HS; Ensminger WD; Layton PB; Gebarski S; Meyer M; Chaffee B; Bender JF; Grillo-Lopez AJ
    Cancer Treat Rep; 1986 Mar; 70(3):353-7. PubMed ID: 3006913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between DT-diaphorase-mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity.
    Gibson NW; Hartley JA; Butler J; Siegel D; Ross D
    Mol Pharmacol; 1992 Sep; 42(3):531-6. PubMed ID: 1406604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential cytotoxicity of diaziquone toward Chinese hamster ovary cells under hypoxic and aerobic exposure conditions.
    O'Brien PJ; Kaul HK; Rauth AM
    Cancer Res; 1990 Mar; 50(5):1516-20. PubMed ID: 2302714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II clinical evaluation of AZQ in colorectal cancer.
    Bedikian AY; Stroehlein JR; Karlin DA; Korinek J; Bodey GP
    Am J Clin Oncol; 1982 Oct; 5(5):535-7. PubMed ID: 7180831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular pharmacology in murine and human leukemic cell lines of diaziquone (NSC 182986).
    Egorin MJ; Fox BM; Spiegel JF; Gutierrez PL; Friedman RD; Bachur NR
    Cancer Res; 1985 Mar; 45(3):992-9. PubMed ID: 3971389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of CNS penetration, tissue distribution, and pharmacology of VP 16-213 by intracarotid and intravenous administration in dogs.
    Savaraj N; Lu K; Feun LG; Burgess MA; Loo TL
    Cancer Invest; 1987; 5(1):11-6. PubMed ID: 3580943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: indoloquinones and diaziridinyl benzoquinones.
    Bailey SM; Suggett N; Walton MI; Workman P
    Int J Radiat Oncol Biol Phys; 1992; 22(4):649-53. PubMed ID: 1544832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of NAD(P)H:quinone oxidoreductase in quinone-mediated p21 induction in human colon carcinoma cells.
    Qiu XB; Cadenas E
    Arch Biochem Biophys; 1997 Oct; 346(2):241-51. PubMed ID: 9343371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of diaziquone.
    Frytak S; Eagan RT; Ames MM; Creagan ET; Nichols WC
    Cancer Treat Rep; 1984; 68(7-8):975-8. PubMed ID: 6744349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumors.
    Chamberlain MC; Prados MD; Silver P; Levin VA
    J Neurooncol; 1988 Dec; 6(4):319-23. PubMed ID: 3221259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sonochemically induced covalent binding of calf thymus DNA by aziridinylquinones.
    Alegria AE; Sanchez-Cruz P; Lopez-Colon D
    Radiat Res; 2005 Oct; 164(4 Pt 1):446-52. PubMed ID: 16187747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sister chromatid exchange induction by diaziquone in human and mouse lymphocytes following both in vivo and in vitro exposures.
    Kligerman AD; Erexson GL; Bryant MF
    Cancer Res; 1988 Jan; 48(1):27-31. PubMed ID: 3334997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of ascorbic acid on the free-radical metabolism of xenobiotics: the example of diaziquone.
    Gutierrez PL
    Drug Metab Rev; 1988; 19(3-4):319-43. PubMed ID: 3068033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Free radicals in quinone containing antitumor agents. The nature of the diaziquone (3,6,-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone) free radical.
    Gutierrez PL; Bachur NR
    Biochim Biophys Acta; 1983 Jul; 758(1):37-41. PubMed ID: 6305426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of patients with recurrent primary brain tumors with AZQ.
    Schold SC; Friedman HS; Bjornsson TD; Falletta JM
    Neurology; 1984 May; 34(5):615-9. PubMed ID: 6538653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Kinetics of accumulation and elimination of 14C-dipine, an antineoplastic drug].
    Korolev GK; Kurasova VG; Kurchatova VV
    Farmakol Toksikol; 1978; 41(4):473-80. PubMed ID: 668875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response variability of human brain tumors to AZQ in tissue culture.
    Kornblith PL; Rosa L; Bona JD; Edwards JA; Matuzic N; Hirschfeld A; Hawkins C
    J Neurooncol; 1986; 4(1):49-54. PubMed ID: 3746385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.